- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07780383
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: First line of the email MUST contain NCT # and Site #.
Copia de seguridad de contactos de estudio
- Nombre: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Número de teléfono: 855-907-3286
- Correo electrónico: Clinical.Trials@bms.com
Ubicaciones de estudio
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Reclutamiento
- CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
-
Contacto:
- Amina Haggag, Site 0001
- Número de teléfono: 714-774-7777
-
-
Florida
-
Bradenton, Florida, Estados Unidos, 34205
- Aún no reclutando
- Local Institution - 0003
-
Contacto:
- Site 0003
-
Daytona Beach, Florida, Estados Unidos, 32117
- Aún no reclutando
- Local Institution - 0005
-
Contacto:
- Site 0005
-
Naples, Florida, Estados Unidos, 34105
- Aún no reclutando
- Local Institution - 0007
-
Contacto:
- Site 0007
-
The Villages, Florida, Estados Unidos, 32162
- Aún no reclutando
- Local Institution - 0006
-
Contacto:
- Site 0006
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30030
- Aún no reclutando
- Local Institution - 0004
-
Contacto:
- Site 0004
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
- Participants must have a BMI of 18.0 to 35.0 kg/m2.
- For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead ECG, Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.
- For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.
- For Part C: Participants must have an Mini Mental State Examination (MMSE) score of ≥ 20 to 28 (inclusive).
- For Part C: Participants must have evidence of positive plasma pTau217.
Exclusion Criteria
- For Parts A and B: Participants must not have a general history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
- For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.
- For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.
- For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).
- Other protocol-defined Inclusion/Exclusion criteria apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Panel A1: BMS986446
|
Specified dose on specified days
Otros nombres:
|
|
Experimental: Panel A2: BMS986446
|
Specified dose on specified days
Otros nombres:
|
|
Experimental: Panel A3: BMS986446
|
Specified dose on specified days
Otros nombres:
|
|
Experimental: Panel B1: BMS986446
|
Specified dose on specified days
Otros nombres:
|
|
Experimental: Panel B2: BMS986446
|
Specified dose on specified days
Otros nombres:
|
|
Experimental: Panel C1: BMS986446
|
Specified dose on specified days
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusion
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Maximum observed concentration (Cmax)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Time of maximum observed concentration (Tmax)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
AUC(INF)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Half-life (T-HALF)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent total body clearance in SC administration (CLT/F)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Total body clearance in IV infusion (CLT)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent volume of distribution of terminal phase in SC administration (Vz/F)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Volume of distribution of terminal phase (VZ)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse events (AEs)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Serious adverse events (SAEs)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
AEs reported as related to BMS-986446
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Incidence of anti-drug antibody (ADA)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for Cmax
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for area under the concentration-time curve (AUC)
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for Cmax
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for AUC
Periodo de tiempo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Local tolerance evaluation
Periodo de tiempo: Up to approximately 5 months
|
This evaluation will assess pain, itching, burning, pressure, and soreness/tenderness (using a Numeric Rating Scale) at the injection site location. |
Up to approximately 5 months
|
|
Cmax
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Tmax
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
AUC(0-T)
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(0-672)
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(INF)
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
T-HALF
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
CLT/F
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Vz/F
Periodo de tiempo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Trough observed plasma concentration (Ctrough)
Periodo de tiempo: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Concentration at the end of a dosing interval (Ctau)
Periodo de tiempo: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Area under the concentration-time curve within a dosing interval (AUC(TAU))
Periodo de tiempo: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Bristol-Myers Squibb, Bristol-Myers Squibb
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CN008-0028
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Marco de tiempo para compartir IPD
See Plan Description
Criterios de acceso compartido de IPD
See Plan Description
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .